References
- DelPrete S A, Maurer L H, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamox ifen in metastatic melanoma. Cancer Treat Rep 1993 1993; 68: 1403–1405
- Rusthoven J I, Quirt I C, Iscoe N A, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996; 14: 2083–2090
- Chiarion Seleni V, Nortilli R, Medici M, et al. BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): results of a randomized phase II study. Proc Am Soc Clin Oncol 1997; 16: 495, (abstract)
- McClay E F, Christen R, Albright K A, et al. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 1992; 52: 6790–6796
- McClay E F, Albright K A, Jones J A, et al. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 1993; 53: 1571–1576
- McClay E F, Albright K D, Jones J A, et al. S.B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 1992; 52: 6790–6796
- McClay E F, Jones J A, Winski P J, et al. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res 1996; 56: 3993–3997
- McClay E F, Albright K A, Jone J A, et al. Tamoxifen modulation of cisplatin cytotxicity in human cancers. Int J Cancer 1993; 55: 1018–1022
- McClay E F, Mastrangelo M J, Berd D, Bellet R E. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 1992; 50: 553–556
- Lattanzi S C, Tosteson T, Chertoff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5: 365–369
- Saba H I, Cruse C W, Wells K E, et al. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: A University of South Florida and H. Lee Moffitt Melanoma Center study. Ann Plast Surg 1992; 28: 60–64
- Richards J M, Gilewski T A, Ramming K, et al. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992; 69: 427–429
- Foshag L J, Morton D L, Nizze J A, Chawla S P. Response to chemotherapy in melanoma patients after active specific immunotherapy (ASI) with melanoma cell vaccine (MCV). Proc Am Soc Clin Oncol 1993; 12: 396, (abstract)
- Crowell E BJ, Higa G M. The chemohormonal therapy of metastatic melanoma: Possible benefit from tamoxifen. West Virginia Med J 1993; 89: 233–235
- Mastrangelo M J, Bellet R E, Berd D. Aggressive chemotherapy for melanoma. Principles and Practice of Oncology; PPO Updates, V T DeVita, S A Hellman, S A Rosenberg. JB Lippincot, Philadelphia 1991; Vol 5(5): 1–11
- Fierro M T, Bertero M, Novelli M, et al. Therapy for metastatic melanoma: Effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993; 3: 127–130
- Johnston S RD, Constenla D O, Moore J, et al. Randomised phase II trial of BCDT (BCNU, cisplatin, dacarbazine and tamoxifen) with or without interferon alpha and interleukin-2 (IL-2) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 1977; 16: 490, (abstract)
- Mitchell M S, Von Eschen K B. Phase III trial of Melacine® melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 1997; 16: 494, (abstract)
- Margolin K, Liu P-Y, Flaherty L, et al. Low-antitumor activity of BCNU, DTIC, cisplatin (DDP) and tamoxifen (TAM) in advanced melanoma: A Southwest Oncology Group study. Proc Am Soc Clin Oncol 1997; 16: 495, (abstract)